valu usd unless otherwis note
playbook
view sever familiar pattern sector perform-r
danah in-lin earn result touch better
compani posit pre-announce
plow upsid acceler growth invest
disappoint might arguabl lack demonstr upsid
news dental spin could slightli delay
due us govern shutdown
as-expect ep organ revenu upsid off-set acceler
growth invest danah result larg consist
posit pre-announce ep would
near high-end guidanc rang better-than-expect organ
growth includ dental repres segment
strongest quarterli growth two year given top-lin upsid
manag took opportun acceler invest spend
across portfolio includ sale market
experi consist typic
playbook find pocket upsid regard
posit invest mainli pull-forward plan action
manag discret around time final danah
disclos time-frame dental spin may slightli delay
due us govern shutdown given backlog sec file
tax rule maintain cash ep estim
high-end re-affirmed guidanc rang price target
biggest surpris likelihood earlier-than-plan complet
dental spin recal separ
initi target time-frame year-end actual complet
spin juli much earlier plan investor hope
repeat acceler time like disappoint
manag state upcom dental spin could delay
middl latter-half initi time-frame attribut
recent us feder govern shutdown creat oner
backlog sec file tax rule
implications/read-across net leverag lowest level
three year end net debt/ebitda
repres lowest level leverag reach sinc
pall acquisit estim danah firepow
roughli low-double-digit billion manag note deal
pipelin remain robust potenti target across everi platform
valuat near high-end rel rang trade
premium peer adjust ep vs target rang
price target assum trade premium
price prior trade day market close estimate unless otherwis note
best-in-class multi-industri name metric
hold much-covet posit among higher
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
spin dental independ publicli trade
compani announc plan spin
dental segment mix stand-alone publicli
trade compani tax-fre transact target
strateg rational dental flexibl
organ invest abl place
bigger spotlight standout portfolionam
nobel biocar recal argument behind
danah success spin-off
balanc sheet fulli reload comfort return
larger deal size recent state
becom comfort return larger multi-
billion dollar deal size vein billion
cepheid acquisit even deploy billion
acquisit estim still
billion firepow could feasibl deploy
next month suggest healthi level balanc sheet
capac deal-mak medium-term
given expens price-tag below-benchmark
expect return major integr stumbl pall
cepheid would damag faith investor
 disciplin also enhanc scrutini
dental segment turnaround given
process spun independ publicli trade
compani
bloomberg capit market estim upside/downside/target
follow spin believ
re-rat target rel price-to-earnings rang given
compani divest cyclic legaci industri
busi assum trade
high-end rang due solid outlook investor
enthusiasm pend dental spin potenti
 premium target group
multipl price-to-earnings adjust ep
cash ep estim impli valuat
support sector perform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
stronger dental perform believ stock
may abl re-rat beyond high-end rel
rang premium target group multipl
adjust ep also see potenti
upsid adjust ep reach level includ
acceler organ growth end market improv
carri execut risk misstep
 integr dental turnaround could weigh
stock addit high-qual defens name
would lag market enter prolong risk-on
environ favor cyclic higher-beta stock could
see price-to-earnings contract premium peer
near low-end target rel rang also
risk end market slowdown result adjust
ep closer valuat
takeaway result
revenu high growth
market high-
single-digit led double-
digit growth china
india us also
high-single-digit
western europ
cash ep consist posit pre-announce led
healthi organ growth report cash ep consist
compani posit pre-announce quarterli earn would
near high-end guidanc rang ep line estim
penni arguabl stale consensu commun posit
pre-announce organ revenu growth stronger expect outpac
estim guidanc led upsid life scienc
diagnost well organ growth dental vs expect flat y/i
given top-lin upsid manag took opportun acceler invest
across portfolio adjust oper margin flat y/i exclud one-tim
cost relat dental spin increment margin soft said
manag note underli margin quarter would bp y/i
strip impact fx tariff overal oper line miss vs
estim compris life scienc diagnost dental
environment appli solut lower-than-expect corpor expens
line lower interest expens higher amort add-back
ad ep upsid final free cash flow convers impress
quarter outstrip histor averag full year free cash
flow convers solid five-year averag
capit market compani report note organ revenu growth estim sector actual
reaffirm cash ep guidanc set in-lin guidanc
expect re-affirmed cash ep guidanc set
outlook meet along forecast organ revenu
growth addit compani issu initi cash ep guidanc
line consensu high-end estim
term put take manag expect incur million foreign
exchang revenu headwind full year million hit equat
ep overal fx headwind expect greater addit
compani still estim million tariff-rel cost inflat headwind
million increment impact vs final forecast organ
growth reflect downtick led continu
strength life scienc maintain cash ep estim lower
estim high-end guidanc
framework assum
grow high-single-digit
consecut year
organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
exhibit danah earn guidanc vs estim consensu
dental sale ahead upcom spin mid- dental segment
achiev organ growth reflect strongest quarterli perform
two year manag call encourag sign stabl sell-out data channel
particularli among north american tradit consum equip addit
segment china busi million annual revenu segment mix achiev
double-digit growth quarter thank local effort region demand
profit core oper margin segment contract bp y/i
larg due increas invest spend includ new product develop
full year guidanc framework assum dental maintain low-single-
digit organ revenu growth final manag state busi like
spun manag net debt/ebitda leverag ratio
life scienc despit achiev solid organ growth quarter oper
margin life scienc contract bp y/i due headwind fx acceler
growth invest purchas account beckman life scienc sciex pall
phenomenex deliv high-single-digit organ growth quarter manag
note phenomenex increas size address market two
year sinc acquir meanwhil achiev mid-teen revenu growth
contribut nice segment overal profit top-lin profil
acquisit anniversari april
diagnost diagnost report organ revenu growth bp core
oper margin expans quarter beckman diagnost leica biosystem
saw organ revenu increas mid-single-digit radiomet achiev high-single-
digit growth thank share gain acut care market addit cepheid
report double-digit organ growth hit signific mileston place
instrument global expand market-lead instal base
revenu growth consist mid-single-digit across product id water
qualiti qualiti hach abl leverag best-in-class digit market
capabl expand address market achiev high-single-digit organ growth
across municip industri end market includ china meanwhil trojan
organ revenu declin due tough y/i comp manag note project
bid activ underli market demand remain encourag chemtreat high-
single-digit organ growth driven primarili strength across food chemic oil
 ga end market final product id platform saw high-single-digit organ growth
videojet off-set low-single-digit declin esko x-rite
manag note
recent us feder
could slightli delay
separ dental
mid- given
backlog sec file
upcom catalyst point monitor
plan separ dental independ publicli trade compani
announc intend spin dental segment revenu stand-alone
publicli trade compani tax-fre transact time-frame complet
spin sometim manag note recent us feder govern
shutdown may slightli delay mid- given segment multipl year
market challeng poor growth hard us see move capitul
especi time manag attent invest
dental turnaround said segment rel stronger posit today
expand gross margin bp sinc consolid number
opco three reduc manufactur back-offic footprint
past three year manag primari rational separ dental view
flexibl organ inorgan invest includ
stand-alone compani recal argument led manag
success spin current group execut presid dental
amir aghdaei becom presid ceo spinco former aher cfo
coma serv special advisor
balanc sheet fulli reload roughli low-double-digit billion capac
estim danah firepow feasibl deploy next month
roughli low-double-digit billion compani end net debt-to-ebitda
lowest level leverag ratio reach sinc pall
acquisit suggest ampl capac deal-mak manag
comment pipelin remain robust potenti target across everi platform
primari criteria double-digit year-thre small bolt-on deal
year-fiv larger acquisit key characterist attract target includ
fragment market secular growth driver high barrier entri compani
strong brand direct busi custom intimaci recur revenu
final manag emphas pull back capit deploy
plan even work separ dental tax-fre spin
rel price-to-earnings trade near high-end target rang share
current trade premium multi-industri sector report ep
cash ep believ stock trade premium target
group multipl high-end histor rel rang impli
price target support sector perform rate current level
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri peer group averag
surpris premium group given outsiz a-driven
amort premium price-to-earnings
share price trade premium weight averag price-to-earnings
publicli trade peer report ep cash ep believ
deserv premium reflect market leadership db toolkit
share price assum after-tax cost capit beta annual sale
growth termin growth rate
compani report capit market estim
millionsmarjunsepdecmarjunsepdecmarjunsepdecmarjunsepdecseg revenueslif environment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens incom exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper electr equip multi-industri
follow spin fortiv corp believ re-rat higher beyond
rel price-to-earnings rang within trade histor target
rel rang given divest cyclic legaci industri
busi believ trade high-end rang due solid
outlook investor enthusiasm pend dental spin potenti
 catalyst premium target group multipl price-to-earnings
adjust ep cash ep impli valuat support sector
risk rate price target
acquisit one acquisit compani multi-industri sector
alway risk overpay experienc integr difficulti major
deal given pricey pall cepheid acquisit multipl believ integr
stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
four segment life scienc diagnost dental environment appli solut
also oper differenti framework growth lean leadership tool
process known danah busi system across aspect oper includ
product develop qualiti control global sourc sale market danah
modestli headquart washington employ peopl global
